Drugs

, Volume 74, Issue 16, pp 1841–1848 | Cite as

Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes?

Current Opinion

Abstract

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are currently among the most commonly prescribed pharmaceutical agents worldwide. Apart from their well-established therapeutic value in cardiovascular disease, there is a long-standing debate on their potential association with cancer. To obtain and discuss the existing clinical evidence, an overview of meta-analysis articles addressing this issue was carried out. As of today, the accumulated evidence does not support the hypothesis that statins affect the risk of developing cancer, when they are taken at low doses for managing hypercholesterolaemia. However, current data cannot exclude an increased cancer risk in elderly patients associated with hydrophilic statin use, or decreases in the risks of certain cancers, such as gastric, oesophageal, liver, colorectal and advanced/aggressive prostate cancer. On the other hand, some recent observational studies have provided evidence that statins might be useful in modifying the prognosis of patients diagnosed with malignancy. Until a definitive benefit is demonstrated in randomized controlled trials, statins cannot be recommended either for cancer prevention or for modifying cancer-related outcomes. Further research is warranted to clarify the potential role(s) of statins in the prevention and treatment of cancer.

Keywords

Statin Pravastatin Rosuvastatin Fluvastatin Pitavastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used in the preparation of this manuscript.

Dr. Stefanos Bonovas has no conflicts of interest to declare.

References

  1. 1.
    Mann D, Reynolds K, Smith D, et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208–15.CrossRefGoogle Scholar
  2. 2.
    Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe: data from administrative databases. BMJ. 2004;328:385–6.CrossRefGoogle Scholar
  3. 3.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRefGoogle Scholar
  4. 4.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.CrossRefGoogle Scholar
  5. 5.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.CrossRefGoogle Scholar
  6. 6.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001–9.CrossRefGoogle Scholar
  7. 7.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.CrossRefGoogle Scholar
  8. 8.
    The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
  9. 9.
    Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935–59.CrossRefGoogle Scholar
  10. 10.
    Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefGoogle Scholar
  11. 11.
    Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463–4.CrossRefGoogle Scholar
  12. 12.
    Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.CrossRefGoogle Scholar
  13. 13.
    Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–92.CrossRefGoogle Scholar
  14. 14.
    LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 2001;88:291–3.CrossRefGoogle Scholar
  15. 15.
    Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109:III39–43.PubMedGoogle Scholar
  16. 16.
    Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J. 2003;24:225–48.CrossRefGoogle Scholar
  17. 17.
    Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.CrossRefGoogle Scholar
  18. 18.
    Bonovas S, Tsantes A, Drosos T, et al. Cancer chemoprevention: a summary of the current evidence. Anticancer Res. 2008;28:1857–66.PubMedGoogle Scholar
  19. 19.
    Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–42.CrossRefGoogle Scholar
  20. 20.
    Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005;2:82–9.CrossRefGoogle Scholar
  21. 21.
    Pisanti S, Picardi P, Ciaglia E, et al. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 2014;88C:84–98.CrossRefGoogle Scholar
  22. 22.
    Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 2005;14:1897–8.CrossRefGoogle Scholar
  23. 23.
    Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55–60.CrossRefGoogle Scholar
  24. 24.
    Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA. 1996;275:67–9.CrossRefGoogle Scholar
  25. 25.
    Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334–6.CrossRefGoogle Scholar
  26. 26.
    Harris RP, Helfand M, Woolf SH, et al. Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35.CrossRefGoogle Scholar
  27. 27.
    Nikolopoulos GK, Bagos PG, Bonovas S. Developing the evidence base for cancer chemoprevention: use of meta-analysis. Curr Drug Targets. 2011;12:1989–97.CrossRefGoogle Scholar
  28. 28.
    Zhang XL, Liu M, Qian J, et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J Clin Pharmacol. 2014;77:458–65.CrossRefGoogle Scholar
  29. 29.
    Bonovas S, Lytras T, Sitaras NM. Statin use and breast cancer: do we need more evidence and what should this be? Expert Opin Drug Saf. 2014;13:271–5.CrossRefGoogle Scholar
  30. 30.
    Lv HL, Jin DM, Liu M, et al. Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. Pharmacol Res. 2014;81:64–73.CrossRefGoogle Scholar
  31. 31.
    Lytras T, Nikolopoulos G, Bonovas S. Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol. 2014;20:1858–70.CrossRefGoogle Scholar
  32. 32.
    Li X, Wu XB, Chen Q. Statin use is not associated with reduced risk of skin cancer: a meta-analysis. Br J Cancer. 2014;110:802–7.CrossRefGoogle Scholar
  33. 33.
    Wu XD, Zeng K, Xue FQ, et al. Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol. 2013;69:1855–60.CrossRefGoogle Scholar
  34. 34.
    Beales IL, Hensley A, Loke Y. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther. 2013;4:69–79.CrossRefGoogle Scholar
  35. 35.
    Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol. 2013;24:1721–30.CrossRefGoogle Scholar
  36. 36.
    Park HS, Schoenfeld JD, Mailhot RB, et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol. 2013;24:1427–34.CrossRefGoogle Scholar
  37. 37.
    Singh S, Singh AG, Singh PP, et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:620–9.CrossRefGoogle Scholar
  38. 38.
    Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2013;22:229–34.CrossRefGoogle Scholar
  39. 39.
    Zhang XL, Geng J, Zhang XP, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013;24:769–76.CrossRefGoogle Scholar
  40. 40.
    Scosyrev E, Tobis S, Donsky H, et al. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int. 2013;111:E71–7.CrossRefGoogle Scholar
  41. 41.
    Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323–32.CrossRefGoogle Scholar
  42. 42.
    Wang J, Li C, Tao H, et al. Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials. PLoS One. 2013;8:e77950.CrossRefGoogle Scholar
  43. 43.
    Tan M, Song X, Zhang G, et al. Statins and the risk of lung cancer: a meta-analysis. PLoS One. 2013;8:e57349.CrossRefGoogle Scholar
  44. 44.
    Mass AY, Agalliu I, Laze J, et al. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol. 2012;188:786–91.CrossRefGoogle Scholar
  45. 45.
    Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.Google Scholar
  46. 46.
    Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135:261–9.CrossRefGoogle Scholar
  47. 47.
    Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23:1099–111.CrossRefGoogle Scholar
  48. 48.
    Bansal D, Undela K, D’Cruz S, et al. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691.CrossRefGoogle Scholar
  49. 49.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.Google Scholar
  50. 50.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.Google Scholar
  51. 51.
    Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2010;19:196–202.CrossRefGoogle Scholar
  52. 52.
    Bonovas S, Nikolopoulos G, Filioussi K, et al. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol. 2010;25:29–35.CrossRefGoogle Scholar
  53. 53.
    Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol. 2008;103:2646–51.CrossRefGoogle Scholar
  54. 54.
    Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44:2122–32.CrossRefGoogle Scholar
  55. 55.
    Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123:899–904.CrossRefGoogle Scholar
  56. 56.
    Taylor ML, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev. 2008;17:259–68.CrossRefGoogle Scholar
  57. 57.
    Bonovas S, Filioussi K, Tsantes A, et al. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol. 2007;64:255–62.CrossRefGoogle Scholar
  58. 58.
    Bonovas S, Filioussi K, Flordellis CS, et al. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007;25:3462–8.CrossRefGoogle Scholar
  59. 59.
    Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ. 2007;176:649–54.CrossRefGoogle Scholar
  60. 60.
    Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–43.CrossRefGoogle Scholar
  61. 61.
    Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst. 2006;98:1538–46.CrossRefGoogle Scholar
  62. 62.
    Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24:4808–17.CrossRefGoogle Scholar
  63. 63.
    Stein EA, Corsini A, Gimpelewicz CR, et al. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006;60:1028–34.CrossRefGoogle Scholar
  64. 64.
    Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80.CrossRefGoogle Scholar
  65. 65.
    Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606–12.CrossRefGoogle Scholar
  66. 66.
    Dellavalle RP, Drake A, Graber M, et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev. 2005;(4):CD003697.Google Scholar
  67. 67.
    Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716–23.CrossRefGoogle Scholar
  68. 68.
    Bonovas S, Nikolopoulos G, Sitaras NM. Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted. J Clin Oncol. 2013;31:4160.Google Scholar
  69. 69.
    Bonovas S, Sitaras NM. Statins and cancer risk: a confounded association. Gastroenterology 2009;137:740.Google Scholar
  70. 70.
    Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf. 2010;9:603–21.CrossRefGoogle Scholar
  71. 71.
    Kumar AS, Campbell M, Benz CC, et al. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006;24:2127.Google Scholar
  72. 72.
    Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol. 2006;24:2128–9.CrossRefGoogle Scholar
  73. 73.
    Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group. Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.CrossRefGoogle Scholar
  74. 74.
    Shepherd J, Blauw GJ, Murphy MB. The PROSPER trial. Authors’ reply. Lancet. 2003;361:428.Google Scholar
  75. 75.
    Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931–40.CrossRefGoogle Scholar
  76. 76.
    Ford I, Murray H, Packard CJ, et al. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–86.CrossRefGoogle Scholar
  77. 77.
    Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem. 2004;279:33079–84.CrossRefGoogle Scholar
  78. 78.
    Stone BG, Evans CD, Prigge WF, et al. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J Lipid Res. 1989;30:1943–52.PubMedGoogle Scholar
  79. 79.
    Bonovas S, Nikolopoulos G, Sitaras NM. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet. 2011;377:715.Google Scholar
  80. 80.
    Bonovas S, Nikolopoulos G, Sitaras NM. Commentary on pravastatin and cancer: need for individual patient data meta-analyses. Pharmacoepidemiol Drug Saf. 2010;19:203–4.CrossRefGoogle Scholar
  81. 81.
    Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792–802.CrossRefGoogle Scholar
  82. 82.
    Caporaso NE. Statins and cancer-related mortality—let’s work together. N Engl J Med. 2012;367:1848–50.CrossRefGoogle Scholar
  83. 83.
    Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012;324:1–12.CrossRefGoogle Scholar
  84. 84.
    Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol. 2003;23:1055–69.PubMedGoogle Scholar
  85. 85.
    Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9:10–9.PubMedGoogle Scholar
  86. 86.
    Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem. 2009;106:975–83.CrossRefGoogle Scholar
  87. 87.
    Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014;32(28):3177–3183.Google Scholar
  88. 88.
    Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461–8.CrossRefGoogle Scholar
  89. 89.
    Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011;29:585–93.CrossRefGoogle Scholar
  90. 90.
    Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109:573–9.CrossRefGoogle Scholar
  91. 91.
    Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013;109:318–24.CrossRefGoogle Scholar
  92. 92.
    Sendur MA, Aksoy S, Yazici O, et al. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol. 2014;31:835.CrossRefGoogle Scholar
  93. 93.
    Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15:e461–8.CrossRefGoogle Scholar
  94. 94.
    Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS One. 2013;8:e75088.CrossRefGoogle Scholar
  95. 95.
    Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32:5–11.CrossRefGoogle Scholar
  96. 96.
    Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer. 2001;84:886–91.CrossRefGoogle Scholar
  97. 97.
    Choi SK, Min GE, Jeon SH, et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol. 2013;1:365–8.CrossRefGoogle Scholar
  98. 98.
    Nam DH, Lee H, Park JC, et al. Long-term statin therapy improves oncological outcome after radical gastrectomy for stage II and III gastric cancer. Anticancer Res. 2014;34:355–61.PubMedGoogle Scholar
  99. 99.
    Hawk E, Viner JL. Statins and cancer—beyond the “one drug, one disease” model. N Engl J Med. 2005;352:2238–9.CrossRefGoogle Scholar
  100. 100.
    Kim K. Statin and cancer risks: from tasseomancy of epidemiologic studies to meta-analyses. J Clin Oncol. 2006;24:4796–7.CrossRefGoogle Scholar
  101. 101.
    US National Institutes of Health. ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 20 Sep 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of Pharmacology, School of MedicineUniversity of AthensAthensGreece
  2. 2.Laboratory of Drug Regulatory PoliciesIRCCS Mario Negri Institute for Pharmacological ResearchMilanItaly

Personalised recommendations